Phase III results: tiotropium* Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment

• First Phase III data for tiotropium delivered by the Respimat® SoftMist ^TM inhaler in asthma also demonstrate significant improvements in lung function in these patients ^1,2
• Studies are part of Boehringer Ingelheim’s comprehensive ongoing Phase III UniTinA-asthma ^TM programme
• A significant proportion of asthma patients remain symptomatic despite current treatment options and may have asthma exacerbations ³

Ingelheim, Germany, 3rd September, 2012 – Data from the PrimoTinA-asthma^TM Phase III studies presented for the first time today at the 2012 European Respiratory Society (ERS) congress show that tiotropium significantly reduced asthma exacerbations in patients who remain symptomatic despite treatment with at least ICS^† /LABA^‡ .¹

Tiotropium also significantly improved lung function in symptomatic asthma patients on ICS/LABA.²

These data are also being published simultaneously online in the New England Journal of Medicine available at http://www.nejm.org.